High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry

Maria Chiara Mimmi, Paola Picotti, Alessandra Corazza, Elena Betto, Carlo E. Pucillo, Laura Cesaratto, Carla Cedolini, Viviana Londero, Chiara Zuiani, Massimo Bazzocchi, Gennaro Esposito

Research output: Contribution to journalArticle

Abstract

Background: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures. Methods: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using high-resolution 1H NMR spectroscopy to complement the mass spectrometry results. Results: The contents of Cho, PCho and GPCho in breast tissue extracts were estimated by LC/ESI-MS based on standard compound calibration curves. Sharply increased ratios of phosphorylated-to-unphosphorylated metabolites, PCho/ Cho and (PCho+GPCho)/Cho, were observed in all tumor samples, although without discrimination between benign and malignant lesions, contrary to samples from healthy individuals and from those with fibrocystic disease. Conclusions: The assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. In addition to high sensitivity, the approach also shows a resolution advantage for assaying choline derivatives compared to NMR, and could complement the latter.

Original languageEnglish (US)
Pages (from-to)317-324
Number of pages8
JournalClinical Chemistry and Laboratory Medicine
Volume49
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Choline
Phosphorylcholine
Mass spectrometry
Mass Spectrometry
Electrospray ionization
Electrospray Ionization Mass Spectrometry
Tissue
Biopsy
Breast Neoplasms
Liquid chromatography
Metabolites
Liquid Chromatography
Tissue Extracts
Magnetic Resonance Spectroscopy
Nuclear magnetic resonance spectroscopy
Breast
Derivatives
Calibration
Tumors
Magnetic Resonance Imaging

Keywords

  • breast cancer
  • breast tissue metabonomics
  • choline metabolites
  • mass spectrometry metabonomics
  • tumor marker detection by nuclear magnetic resonance and mass spectrometry

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry. / Mimmi, Maria Chiara; Picotti, Paola; Corazza, Alessandra; Betto, Elena; Pucillo, Carlo E.; Cesaratto, Laura; Cedolini, Carla; Londero, Viviana; Zuiani, Chiara; Bazzocchi, Massimo; Esposito, Gennaro.

In: Clinical Chemistry and Laboratory Medicine, Vol. 49, No. 2, 01.02.2011, p. 317-324.

Research output: Contribution to journalArticle

Mimmi, MC, Picotti, P, Corazza, A, Betto, E, Pucillo, CE, Cesaratto, L, Cedolini, C, Londero, V, Zuiani, C, Bazzocchi, M & Esposito, G 2011, 'High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry', Clinical Chemistry and Laboratory Medicine, vol. 49, no. 2, pp. 317-324. https://doi.org/10.1515/CCLM.2011.060
Mimmi, Maria Chiara ; Picotti, Paola ; Corazza, Alessandra ; Betto, Elena ; Pucillo, Carlo E. ; Cesaratto, Laura ; Cedolini, Carla ; Londero, Viviana ; Zuiani, Chiara ; Bazzocchi, Massimo ; Esposito, Gennaro. / High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry. In: Clinical Chemistry and Laboratory Medicine. 2011 ; Vol. 49, No. 2. pp. 317-324.
@article{3c44314487ec4fd58884aa953f7f5ff0,
title = "High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry",
abstract = "Background: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures. Methods: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using high-resolution 1H NMR spectroscopy to complement the mass spectrometry results. Results: The contents of Cho, PCho and GPCho in breast tissue extracts were estimated by LC/ESI-MS based on standard compound calibration curves. Sharply increased ratios of phosphorylated-to-unphosphorylated metabolites, PCho/ Cho and (PCho+GPCho)/Cho, were observed in all tumor samples, although without discrimination between benign and malignant lesions, contrary to samples from healthy individuals and from those with fibrocystic disease. Conclusions: The assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. In addition to high sensitivity, the approach also shows a resolution advantage for assaying choline derivatives compared to NMR, and could complement the latter.",
keywords = "breast cancer, breast tissue metabonomics, choline metabolites, mass spectrometry metabonomics, tumor marker detection by nuclear magnetic resonance and mass spectrometry",
author = "Mimmi, {Maria Chiara} and Paola Picotti and Alessandra Corazza and Elena Betto and Pucillo, {Carlo E.} and Laura Cesaratto and Carla Cedolini and Viviana Londero and Chiara Zuiani and Massimo Bazzocchi and Gennaro Esposito",
year = "2011",
month = "2",
day = "1",
doi = "10.1515/CCLM.2011.060",
language = "English (US)",
volume = "49",
pages = "317--324",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "2",

}

TY - JOUR

T1 - High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry

AU - Mimmi, Maria Chiara

AU - Picotti, Paola

AU - Corazza, Alessandra

AU - Betto, Elena

AU - Pucillo, Carlo E.

AU - Cesaratto, Laura

AU - Cedolini, Carla

AU - Londero, Viviana

AU - Zuiani, Chiara

AU - Bazzocchi, Massimo

AU - Esposito, Gennaro

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures. Methods: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using high-resolution 1H NMR spectroscopy to complement the mass spectrometry results. Results: The contents of Cho, PCho and GPCho in breast tissue extracts were estimated by LC/ESI-MS based on standard compound calibration curves. Sharply increased ratios of phosphorylated-to-unphosphorylated metabolites, PCho/ Cho and (PCho+GPCho)/Cho, were observed in all tumor samples, although without discrimination between benign and malignant lesions, contrary to samples from healthy individuals and from those with fibrocystic disease. Conclusions: The assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. In addition to high sensitivity, the approach also shows a resolution advantage for assaying choline derivatives compared to NMR, and could complement the latter.

AB - Background: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures. Methods: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using high-resolution 1H NMR spectroscopy to complement the mass spectrometry results. Results: The contents of Cho, PCho and GPCho in breast tissue extracts were estimated by LC/ESI-MS based on standard compound calibration curves. Sharply increased ratios of phosphorylated-to-unphosphorylated metabolites, PCho/ Cho and (PCho+GPCho)/Cho, were observed in all tumor samples, although without discrimination between benign and malignant lesions, contrary to samples from healthy individuals and from those with fibrocystic disease. Conclusions: The assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. In addition to high sensitivity, the approach also shows a resolution advantage for assaying choline derivatives compared to NMR, and could complement the latter.

KW - breast cancer

KW - breast tissue metabonomics

KW - choline metabolites

KW - mass spectrometry metabonomics

KW - tumor marker detection by nuclear magnetic resonance and mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=79952079271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952079271&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2011.060

DO - 10.1515/CCLM.2011.060

M3 - Article

C2 - 21143022

AN - SCOPUS:79952079271

VL - 49

SP - 317

EP - 324

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 2

ER -